EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ADVB: Advanced Biomed Inc

10 Nov 25 09:00
LAST:

0.4080

CHANGE:
 0.00		OPEN:
0.4003		HIGH:
0.4080		ASK:
0.0000		VOLUME:
23.0K
CHG(%):
0.49		PREV:
0.4060		LOW:
0.3600		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Nov 250.40030.40800.36000.408023.0K
07 Nov 250.43010.43020.40140.4060275.0K
06 Nov 250.44000.46770.42000.4395456.7K
05 Nov 250.45360.48560.43510.4428211.8K
04 Nov 250.45000.47700.44200.4557282.7K
03 Nov 250.46800.48200.45100.4603557.0K
31 Oct 250.55470.58850.47210.48061.82M
30 Oct 250.45000.65780.44600.567127.26M
29 Oct 250.45000.47080.44590.4553186.5K
28 Oct 250.45120.45730.43010.4409160.5K

COMPANY PROFILE

Name:Advanced Biomed Inc
About:Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Sector:Healthcare
Address:122 East 42nd Street, New York, NY, United States, 10168
Website:https://www.advanbiomed.com
ISIN:US00752P1049
FIGI:BBG01HW4B3M4

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.435.5%
MA10:0.4611.7%
MA20:0.4510.1%
MA50:0.4613.7%
MA100:0.5125.4%
STO9:0.79 
STO14:0.79 
RSI14:38.41 
WPR14:-98.76 
MTM14:-0.03
ROC14:-0.07 
ATR:0.06 
Week High:0.4919.0%
Week Low:0.3613.3%
Month High:0.6661.2%
Month Low:0.36
Volatility:30.60